^
Association details:
| Biomarker: | BRCA2 A902fs*2 |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) + cabazitaxel (Microtubule inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
Published date:
05/17/2021
Excerpt:
A 37-year old man with Pca...The patient underwent 19 courses of docetaxel (60 mg/m2) and five courses of cabazitaxel (25 mg/m2) thereafter. Docetaxel reduced the PSA by 85%; however, cabazitaxel induced no PSA response. After the disease progressed while the patient underwent taxane-based chemotherapy, we performed a genetic test by FoundationONE CDx...Genetic testing revealed a frameshift mutation with a stop codon two positions further in the BRCA2 (pA902fs*2)...
DOI:
10.1016/j.eucr.2021.101712
Test:
